EGFR and non-small cell lung carcinoma: Zhang's study also indicated that anti‐PD‐1 inhibitors toripalimab plus chemotherapy showed a promising anti‐tumor efficacy with a tolerable safety profile for NSCLC patients after progression on EGFR TKI therapies (ORR 54.8%, mPFS 7.6 months) [27].